<DOC>
	<DOCNO>NCT01137851</DOCNO>
	<brief_summary>The purpose study assess impact patient cost share treatment discontinuation biologic agent patient Rheumatoid Arthritis ( RA )</brief_summary>
	<brief_title>Effect Patient Cost Sharing Treatment Discontinuation Among Rheumatoid Arthritis Patients</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<criteria>Patients diagnose Rheumatoid Arthritis ( RA ) newly initiate biologic DMARD ( bDMARD ) study timeframe 1/01/06 3/31/09 . 18 64 year age index date Diagnosis RA study period ( ICD9CM 714.xx ) Evidence least one biologic DMARD interest study timeframe Continuous enrollment study timeframe Both medical pharmacy benefit No evidence claim bDMARD 6month preperiod Patients exclude diagnosis psoriasis , psoriatic arthritis , ankylose spondylitis , Crohn 's disease , ulcerative colitis time study timeframe ; claim Rituxan , IV etanercept , IV adalimumab ; Medicare Medicaid study timeframe</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2010</verification_date>
</DOC>